Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following table presents selected financial information with respect to the Company’s single operating segment for the years ended:

	Three Months Ended March 31,
	2025		2024
Collaboration revenue	$	20,558	$	59,120
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-44	4,734		3,279
ENTR-601-45	2,859		2,538
ENTR-601-50	692		2,643
ENTR-601-51	826		70
Collaboration services	876		753
Other preclinical and discovery	1,257		1,911
Unallocated research and development expenses
Personnel related (including stock-based compensation)	12,756		9,900
Facility related and other	8,074		7,514
Total research and development expenses	32,074		28,608
General and administrative expenses	10,274		9,399
Interest and other income	4,441		4,214
Provision for income taxes	—		1,831
Net (loss) income	$	(17,349)	$	23,496